Pediatric myocardial protection: an overview

B S Allen1, M J Barth, M N Ilbawi

  • 1Division of Cardiovascular Surgery, The Heart Institute for Children, Hope Children's Hospital, Oak Lawn, IL 60453, USA.

Insights

This study presents a new bypass and cardioplegic strategy to protect infant hearts during surgery, significantly improving outcomes for pediatric patients. The approach minimizes intraoperative injury, enhancing safety for vulnerable young hearts undergoing complex procedures.

Area of Science:

  • Pediatric Cardiac Surgery
  • Cardiovascular Research
  • Medical Device Infrastructure

Background:

  • Infant hearts are highly susceptible to surgical damage due to preoperative hypertrophy, cyanosis, and ischemia.
  • Existing strategies for myocardial protection in pediatric patients require enhancement to mitigate risks.
  • Understanding vulnerability factors like cyanosis and ischemia is crucial for developing effective interventions.

Purpose of the Study:

  • To describe the experimental infrastructure and clinical application of a novel bypass and cardioplegic strategy.
  • To evaluate the strategy's effectiveness in limiting intraoperative injury and improving postoperative outcomes in pediatric cardiac surgery.
  • To present data on cardioplegic management principles applied in this technique.

Main Methods:

  • Development of a comprehensive bypass and cardioplegic strategy incorporating normoxia/hyperoxia bypass starts, leukocyte filtration, and warm induction/reperfusion.
  • Utilized multidose blood cardioplegia with modified substrate and electrolyte balance (reduced calcium, increased magnesium).
  • Integrated approach to minimize ischemia, allowing it only when necessary during pediatric surgeries.

Main Results:

  • Successful clinical application in 567 pediatric patients over 2 years at the Heart Institute for Children and University of Illinois hospital.
  • Included 72 patients with hypoplastic left heart syndrome over 4 years, demonstrating the strategy's versatility.
  • The strategy effectively limited intraoperative injury and improved postoperative outcomes.

Conclusions:

  • The described comprehensive bypass and cardioplegic strategy provides enhanced myocardial protection for infant hearts.
  • Application of these principles can significantly improve the safety and outcomes of pediatric cardiac surgeries.
  • This integrated approach represents a significant advancement in managing vulnerable infant hearts during bypass.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...